Capsugel Announces Expansion at Quakertown Facility

Sep 07, 2016
By Pharmaceutical Technology Editors
Volume 11, Issue 10

On Sept. 7, 2016, Capsugel announced that it will be expanding its Quakertown, PA facility to meet demand for micronization services for clinical and commercial manufacturing. The expansion will double the size of its current pilot-scale capacity for clinical-trial quantities and increase the number of suites for commercial manufacturing.

The Quakertown facility, which Capsugel acquired as part of its purchase of Xcelience and Powdersize in January 2016, operates as a full-service provider of particle-size reduction and particle-size control/classification technologies for pharmaceutical customers. The acquisition expanded the company’s suite of bioavailability tools aimed at improving the bioavailability of APIs with either dissolution or solubility challenges. In addition to enabling increased capacity, the added suites will include single-use containment technologies to accommodate potent and highly potent compounds. The new equipment and suites are scheduled to be operational by January 2017.

Source: Capsugel

native1_300x100
lorem ipsum